Abstract: In certain aspects, a memory device includes an array of memory cells, a plurality of word lines coupled to the array of memory cells, and a plurality of peripheral circuits coupled to the array of memory cells and configured to control the array of memory cells. A first peripheral circuit of the plurality of peripheral circuits includes a first three-dimensional (3D) transistor coupled to the array of memory cells through at least one of the plurality of bit lines. The first 3D transistor includes a 3D semiconductor body, and a gate structure in contact with a plurality of sides of the 3D semiconductor body. The gate structure includes a gate dielectric and a gate electrode.

Abstract: An oral dosage form of metformin and preparation method is provided. The oral dosage form comprises a metformin-containing core and an encapsulating controlled membrane film, and the controlled membrane film is provided with at least one passageway allowing metformin to release out of the core therethrough in an aqueous environment. The oral dosage form is designed such that upon dissolving in a medium with a pH 6.8 at 37° C., less than 30% of metformin is released at 4 hours, and less than 92% of the metformin is released at 24 hours. The oral dosage form is further designed to provide a maximum plasma concentration of the metformin or the pharmaceutically acceptable salt thereof in the subject from approximately 8-24 hours after a single-dose oral administration.

Abstract: In certain aspects, a memory device includes an array of memory cells, a plurality of word lines coupled to the array of memory cells, and a plurality of peripheral circuits coupled to the array of memory cells and configured to control the array of memory cells. A first peripheral circuit of the plurality of peripheral circuits includes a first three-dimensional (3D) transistor coupled to the array of memory cells through at least one of the plurality of word lines. The first 3D transistor includes a 3D semiconductor body, and a gate structure in contact with a plurality of sides of the 3D semiconductor body. The gate structure includes a gate dielectric and a gate electrode.

Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.

Abstract: An oral dosage form of ticagrelor includes a core and a semi-permeable membrane coating the core. The core comprises a first drug layer and a push layer. The first drug layer contains ticagrelor that is sufficient to deliver an effective amount of the drug over an intended delivery time. The push layer comprises a swelling agent and an osmogen agent. The semi-permeable membrane has at least one passageway formed therethrough, positionally configured to face the first drug layer, but not to face the push layer, of the core, and functionally configured to allow the ticagrelor to realize an extended release out of the core upon contacting an aqueous environment. The dosage form optionally further includes a second ticagrelor-containing drug layer coating the semi-permeable membrane, thereby providing a starting effective dose upon administration. The dosage form can realize once-a-day administration of ticagrelor of patients in need thereof.

Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.

Abstract: Disclosed in the application are a semiconductor device structure and a manufacturing method thereof. The semiconductor device structure includes: a semiconductor substrate; active regions and isolation structures located in the semiconductor substrate and arranged alternately at intervals in a first direction, the active regions extending in a second direction perpendicular to the first direction; gate structures located at least on the active regions; and virtual structures located at least on the isolation structures, a spacing existing between the gate structures and the virtual structures in the second direction. The active regions further include source-doped regions and drain-doped regions located on two sides of the gate structures, projections of the virtual structures on the isolation structures are located between the source-doped regions, or projections of the virtual structures on the isolation structures are located between the drain-doped regions.

Abstract: An oral dosage form of ticagrelor includes a core and a semi-permeable membrane coating the core. The core comprises a first drug layer and a push layer. The first drug layer contains ticagrelor that is sufficient to deliver an effective amount of the drug over an intended delivery time. The push layer comprises a swelling agent and an osmogen agent. The semi-permeable membrane has at least one passageway formed therethrough, positionally configured to face the first drug layer, but not to face the push layer, of the core, and functionally configured to allow the ticagrelor to realize an extended release out of the core upon contacting an aqueous environment. The dosage form optionally further includes a second ticagrelor-containing drug layer coating the semi-permeable membrane, thereby providing a starting effective dose upon administration. The dosage form can realize once-a-day administration of ticagrelor of patients in need thereof.

Abstract: In certain aspects, a memory device includes an array of memory cells, a plurality of word lines coupled to the array of memory cells, and a plurality of peripheral circuits coupled to the array of memory cells and configured to control the array of memory cells. A first peripheral circuit of the plurality of peripheral circuits includes a first three-dimensional (3D) transistor coupled to the array of memory cells through at least one of the plurality of word lines. The first 3D transistor includes a 3D semiconductor body, and a gate structure in contact with a plurality of sides of the 3D semiconductor body. The gate structure includes a gate dielectric and a gate electrode.

Abstract: In certain aspects, a memory device includes an array of memory cells and a plurality of peripheral circuits coupled to the array of memory cells and configured to control the array of memory cells. A first peripheral circuit of the plurality of peripheral circuits includes a first three-dimensional (3D) transistor. The first 3D transistor includes a 3D semiconductor body, and a gate structure in contact with a plurality of sides of the 3D semiconductor body. The gate structure includes a gate dielectric and a gate electrode. The gate electrode includes a metal, and the gate dielectric has a thickness between 1.8 nm and 10 nm.

Abstract: In certain aspects, a memory device includes an array of memory cells, a plurality of word lines coupled to the array of memory cells, and a plurality of peripheral circuits coupled to the array of memory cells and configured to control the array of memory cells. A first peripheral circuit of the plurality of peripheral circuits includes a first three-dimensional (3D) transistor coupled to the array of memory cells through at least one of the plurality of bit lines. The first 3D transistor includes a 3D semiconductor body, and a gate structure in contact with a plurality of sides of the 3D semiconductor body. The gate structure includes a gate dielectric and a gate electrode.

Abstract: In certain aspects, a three-dimensional (3D) memory device includes a first semiconductor structure including an array of memory cells, a second semiconductor structure including a peripheral circuit, and a bonding interface between the first semiconductor structure and the second semiconductor structure. The peripheral circuit includes a 3D transistor. The array of memory cells is coupled to the peripheral circuit across the bonding interface.

Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.

Abstract: A variable capacitor includes a semiconductor substrate, a well region, and a gate electrode. The well region is disposed in the semiconductor substrate. The gate electrode is disposed on the semiconductor substrate, and the gate electrode overlaps a part of the well region in a thickness direction of the semiconductor substrate. A conductivity type of the gate electrode is complementary to a conductivity type of the well region for improving electrical performance of the variable capacitor.

Abstract: An oral dosage form of a pharmaceutical composition for managing diabetes in a subject is provided, which comprises a core, a controlled membrane film, and an outer film. The core comprises a first antidiabetic agent. The controlled membrane film coats the core tablet and can realize a controlled release of the first antidiabetic agent from the core into a portion of a digestive tract of the subject corresponding to a stomach and an upper gastrointestinal tract after the pharmaceutical composition is orally administered to the subject. The controlled membrane film comprises at least one controlling polymer, each selected from an Eudragit polymer, an Aquacoat polymer, or an Ethocel polymer. The outer film comprises a second antidiabetic agent, and coats the controlled membrane film. A method for manufacturing an oral dosage form of a pharmaceutical composition is also provided.

Abstract: Provided are a metformin hydrochloride osmotic pump tablet and a preparation method therefor. According to the preparation method, a hetero-type stamping-prepared metformin hydrochloride tablet core is used, and a controlled-release coating is wrapped outside the stamped metformin hydrochloride tablet core, such that the metformin hydrochloride osmotic pump tablet is prepared.

Abstract: Provided are a metformin hydrochloride osmotic pump tablet and a preparation method therefor. According to the preparation method, a hetero-type stamping-prepared metformin hydrochloride tablet core is used, and a controlled-release coating is wrapped outside the stamped metformin hydrochloride tablet core, such that the metformin hydrochloride osmotic pump tablet is prepared.

Abstract: A supercapacitor having a main energy storage form that is based on the electrode reaction of electrochemical active materials in a thin liquid layer near the inner and outer surfaces of porous electrodes.

Abstract: An exemplary burning system (20) for a liquid crystal display includes a VGA (video graphics array) interface (230), a DVI (digital visual interface) (240), an interface-inverting circuit (220) configured for selectively switching between connectivity with the VGA interface and connectivity with the DVI, and a host computer (250) including a print interface (210). The host computer is configured for burning extended display identification data for the VGA interface into the liquid crystal display via the print interface, the interface-inverting circuit and the VGA interface, and is configured for burning extended display identification data for the DVI into the liquid crystal display via the print interface, the interface-inverting circuit and the DVI.

Abstract: The present invention provides the compositions and processing methods of an environmental-friendly, multiple-effect powder. The compositions of environmental-friendly, multiple-effect powder include: cement, discarded PCB powder, resin, wasted coating powder and volcano mud powder. The environmental-friendly, multiple-effect powder of the present invention can also be widely applied to civil works as a coating/filling material or other composite building materials due to its advantages such as good thermal insulation, noise absorption, water-proofing, resistance to mildew, rustiness and acid/alkali, excellent robustness and moisture retention with better industrial and economic benefits.